Scholarlink

<p>Detection of postoperative minimal residual disease (MRD) using circulating tumor DNA (ctDNA) accurately predicts cancer recurrence and may even guide adjuvant chemotherapy. Cost-effective and easily implementable assays capable of detecting MRD early (within days after surgery) will drive wider clinical adaptation. We developed a rapid, single-tube multiplex quantitative methylation-specific PCR (mqMSP) assay targeting 10 rigorously screened methylation markers. In a preoperative cohort, mqMSP achieved 100% specificity in 96 controls, with an overall sensitivity of 73.1% for CRC. In a postoperative cohort of 246 stage II-III CRC patients with a long follow-up time (7–96 months, median: 48 months), we demonstrated that ctDNA detection by mqMSP at an early timepoint (median: 5 days after surgery) predicted worse disease-free survival (HR 7.43, <i>P</i> &lt; 0.0001) and overall survival (HR 8.81, <i>P</i> &lt; 0.0001). Benefit from completion of recommended adjuvant therapy was only seen for ctDNA-positive patients, but not for ctDNA-negative patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Earlier postoperative ctDNA detection predicts recurrence and adjuvant therapy benefit in stage II-III colorectal cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月20日

查看全文
  • Wenwen Zhang,
  • Chang Xu,
  • Jingmei Wang,
  • Zhengquan Yang,
  • Xiaoyun Xi,
  • Jiajing Zhou,
  • Jiamin An,
  • Rongrong Mu,
  • Zhuo Lu,
  • Jiayi Yu,
  • Zhenni Luo,
  • Lisha Gong,
  • Xingxiu Guo,
  • Jinlei Li,
  • Chaoqiang Zhou,
  • Fangchao Zhu,
  • Jie Pan,
  • Ju Luan,
  • Shengnan Jin,
  • Chunming Ding

摘要

Detection of postoperative minimal residual disease (MRD) using circulating tumor DNA (ctDNA) accurately predicts cancer recurrence and may even guide adjuvant chemotherapy. Cost-effective and easily implementable assays capable of detecting MRD early (within days after surgery) will drive wider clinical adaptation. We developed a rapid, single-tube multiplex quantitative methylation-specific PCR (mqMSP) assay targeting 10 rigorously screened methylation markers. In a preoperative cohort, mqMSP achieved 100% specificity in 96 controls, with an overall sensitivity of 73.1% for CRC. In a postoperative cohort of 246 stage II-III CRC patients with a long follow-up time (7–96 months, median: 48 months), we demonstrated that ctDNA detection by mqMSP at an early timepoint (median: 5 days after surgery) predicted worse disease-free survival (HR 7.43, P < 0.0001) and overall survival (HR 8.81, P < 0.0001). Benefit from completion of recommended adjuvant therapy was only seen for ctDNA-positive patients, but not for ctDNA-negative patients.